 This study will include subjects that have relapsed and refractory multiple myeloma RRMM after treatment with at least 3 prior antimyeloma therapies, including a proteasome inhibitor PI and an immunomodulatory drug IMiD or after development of double-refractoriness to a both a PI and an IMiD. 